854 0 Kommentare LED Medical Diagnostics Inc. Reports 2013 Fourth Quarter and Full Year Results

BURNABY, BRITISH COLUMBIA--(Marketwired - April 15, 2014) - LED Medical Diagnostics Inc. (TSX VENTURE:LMD)(OTCQX:LEDIF)(FRANKFURT:LME) ("LED Medical" or the "Company") today announced its financial results for the fourth quarter and full year ended December 31, 2013, reported in United States dollars and in accordance with International Financial Reporting Standards ("IFRS"). The Company's results are presented in comparison to the fourth quarter and full year ended December 31, 2012. All balances are expressed in United States dollars unless otherwise stated.

Business Highlights

Notable business developments and achievements up to the reporting date included the following:

On December 3, 2013, the Company announced that it entered a non-exclusive distribution partnership with Burkhart Dental Supply in the United States market.
On December 10, 2013, the Company announced that it entered a non-exclusive distribution partnership with Benco Dental Supply in the United States market.
On January 14, 2014, the Company announced that it signed an agreement with the BC Cancer Agency ("BCCA") to create and commercialize a progression-risk assessment test for oral cancer. The test is based on a quantifiable genetic phenomenon known as "Loss of Heterozygosity" or "LOH".
On January 21, 2014, the Company announced that it entered a non-exclusive distribution partnership with Patterson Dental in the United States and Canadian markets.
On February 25, 2014, the Company announced the appointment of Lamar Roberts as president of its wholly owned US subsidiary LED Dental Ltd.
On March 26, 2014, the Company announced the appointment of Dr. Jeffrey Brooks as vice president of imaging of its wholly owned subsidiary LED Dental Ltd.
On April 2, 2014, the Company announced that its wholly owned US operating subsidiary, LED Dental Ltd. released a new brand initiative to further its goal of providing advanced imaging technologies to dental and specialty practices in the United States and Canada. The branding initiative includes a new logo to further unify the business under the LED Imaging name.
On April 3, 2014 the Company announced that the LED Imaging division of its wholly owned subsidiary, LED Dental Ltd., is partnering with Ray Co., Ltd., a subsidiary of Samsung, to sell, install and provide support for the RAYSCAN α - Expert dental imaging system.

"2014 is expected to be a transformational year for LED as our new management team expands our VELscope distribution network and transitions the Company from a single product strategy to a diverse portfolio of digital imaging products," said the Company's CEO, Dr. David Gane. "The execution of our strategy, which will take an investment in time and capital in the current year, is designed to position the Company for long-term, sustainable growth and success as a leading player in the dental imaging market."

Financial Highlights

Financial Position as at December 31, 2013

Working capital as at December 31, 2013 was $4,445,795, which includes cash of $4,358,986. This is compared to negative working capital of $96,749 at December 31, 2012, which included cash of $969,584.

Three-Month Comparative Results

The Company reported revenue of $215,714 for the three months ended December 31, 2013 as compared to $1,389,994 for the three months ended December 31, 2012. Net loss was $1,460,801 for the three months ended December 31, 2013, as compared to a net loss of $174,630 for the three months ended December 31, 2013.

Inclusive of accounting adjustments, the Company's calculated gross margin was 51% for the three months ended December 31, 2013, which is slightly higher as compared to 46% in the three months ended December 31, 2012. Total operating expenses for the three months ended December 31, 2013 were $1,509,487 as compared to $740,547 for the three months ended December 31, 2012, representing a 108% increase. Core operating expenses (excluding stock-based compensation, deferred share unit compensation and other operating expenses) for the three months ended December 31, 2013 were $1,209,950, as compared to $725,989 for the three months ended December 31, 2012, representing a 67% increase.

EBITDA for the three months ended December 31, 2013 was negative $1,238,255 compared to negative $83,502 for the three months ended December 31, 2012.

Twelve-Month Comparative Results

The Company reported revenue of $2,519,574 for the year ended December 31, 2013 as compared to $6,312,754 for the year ended December 31, 2012. Net loss was $6,955,217 for the year ended December 31, 2013 as compared to a net loss of $866,933 for the year ended December 31, 2012.

Gross margin was 46% for the year ended December 31, 2013, a decrease from 57% in the year ended December 31, 2012. Total operating expenses for the year ended December 31, 2013, were $4,812,236 as compared to $4,355,188 for the year ended December 31, 2012, representing a 10% increase. Core operating expenses (excluding stock-based compensation, deferred share unit compensation and other operating expenses) for the year ended December 31, 2013 were $3,291,582, as compared to $4,295,412 for the year ended December 31, 2012, representing a 23% decrease.

EBITDA for the year ended December 31, 2013 was negative $2,120,231, as compared to negative $728,135 for the year ended December 31, 2012.

Financial Statements and Management's Discussion & Analysis

Please see the audited consolidated financial statements and related Management's Discussion & Analysis ("MD&A") for more details. The audited consolidated financial statements for the year ended December 31, 2013 and related MD&A have been reviewed and approved by the Company's Audit Committee and Board of Directors. The Company has prepared this truncated news release to alert investors to its results and that a more detailed explanation and analysis is readily available in the MD&A. These reports have been filed on SEDAR at www.sedar.com and also posted to www.ledmd.com.

Non-IFRS Measures

The following and preceding discussion of financial results includes references to Gross Margin, EBITDA, Core Operating Expenses and Working Capital, which are non-IFRS financial measures. The measure of gross margin is provided as management believes this is a good indicator in evaluating the operating performance of the Company. EBITDA is defined as net loss and comprehensive loss and excludes interest; income taxes; depreciation; amortization; finder's warrants issuance costs; stock-based compensation; deferred share unit compensation; mark to market adjustments on Canadian dollar denominated warrants; foreign exchange gain or loss; and other income. The measure of working capital is provided as management believes this is a good indicator of the operating liquidity available to the Company.

Forward-Looking Statements

This press release contains statements which, to the extent that they are not recitations of historical fact, may constitute forward- looking information under applicable Canadian securities legislation. Such forward-looking statements or information includes financial and other projections as well as statements regarding the Company's future plans, objectives, performance, revenues, growth, profits, operating expenses or the Company's underlying assumptions and the Company's intention to expand its technology beyond dental applications including "costs of production", "capital expenditures", "costs and timing of the development of new products", "hedging practices", "currency exchange rate fluctuations", "requirements for additional capital", "government regulation of medical device operations" and "insurance coverage". Generally, these forward-looking statements can be identified by the use of forward-looking terminology such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", "believes" or variations of such words and phrases or statements that certain actions, events or results "may", "would", "could", "might" or "will be taken", "occur" or "be achieved" or the negative connotation thereof. Persons reading this Management's Discussion and Analysis are cautioned that such statements or information are only predictions, and that the Company's actual future results or performance may be materially different.

Factors that could cause actual events or results to differ materially from those suggested by these forward-looking statements include, but are not limited to: economic conditions; dilution; limited history of profits and operations; operational risk; distributor risks; working capital; potential conflicts of interest; speculative investment; intellectual property risks; disruptions in production; reliance on key personnel; seasonality; management's estimates; development of new customers and products risks; stock price volatility risk; sales and marketing risk; competitors and competition risk; regulatory requirements; reliance on few suppliers; reliance on subcontractors; operating cost and quarterly results fluctuations; fluctuations in exchange rates; product liability and medical malpractice claims; access to credit and additional financing; taxation; market acceptance of the Company's products and services; customer and industry analyst perception of the Company and its technology vision and future prospects; technological change, new products and standards; risks related to acquisitions and international expansion; reliance on large customers; concentration of sales; international operations and sales; management of growth and expansion; dependence upon key personnel and hiring; the Company not adequately protecting its intellectual property; risks related to product defects and product liability; and including, but not limited to, other factors described in the Company's reports filed on SEDAR, including its financial statements and management's discussion and analysis for the year ended December 31, 2013.

In drawing a conclusion or making a forecast or projection set out in the forward-looking information, the Company takes into account the following material factors and assumptions in addition to the above factors: the Company's ability to execute on its business plan; the acceptance of the Company's products and services by its customers; the timing of execution of outstanding or potential customer contracts by the Company; the sales opportunities available to the Company; the Company's subjective assessment of the likelihood of success of a sales lead or opportunity; the Company's historic ability to generate sales leads or opportunities; and that sales will be completed at or above the Company's estimated margins. This list is not exhaustive of the factors that may affect the Company's forward-looking information. These and other factors should be considered carefully and readers should not place undue reliance on such forward-looking information. All forward-looking statements made in this Management's Discussion and Analysis are qualified by this cautionary statement and there can be no assurance that actual results or developments anticipated by the Company will be realized. The Company disclaims any intention or obligation to update or revise forward-looking information, whether as a result of new information, future events or otherwise, except as required by law.

About LED Medical Diagnostics Inc.

Founded in 2003 and headquartered in Burnaby, British Columbia, Canada, LED Medical Diagnostics Inc. is a leading developer of LED- based visualization technologies for the medical industry. The Company is currently listed on the Toronto Stock Exchange (TSX-V) under the symbol "LMD", the OTCQX under the symbol "LEDIF", as well as the Frankfurt Stock Exchange under the symbol "LME". For more information, visit www.ledmd.com.

LED Dental Inc., a wholly-owned subsidiary, is backed by an experienced leadership team dedicated to a higher level of service and support. LED Dental offers advanced diagnostic imaging equipment that seamlessly integrates into dental practices. The Company is committed to providing dental practitioners with the best technology available by identifying and adding strong products to its growing portfolio. Additionally, the company manufactures the award-winning VELscope® Vx Enhanced Oral Assessment System, the first system in the world to apply tissue fluorescence visualization technology to the oral cavity. The VELscope® Vx is now used to conduct more screenings for oral cancer and other oral mucosal diseases than any other adjunctive device. For more information, call 888.541.4614 or visit www.leddental.com.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


LED MEDICAL DIAGNOSTICS INC.
Consolidated Statements of Financial Position
(Expressed in U.S. Dollars)

			December 31,			December 31,
		Notes	2013			2012

Assets
Current assets
	Cash		$	4,358,986		$	969,584
	Restricted cash	4		-			5,026
	Trade and other receivables	5		503,736			1,514,577
	Inventory			412,307			296,467
	Inventory held by distributor	6		165,832			518,400
	Prepaid expenses and deposits			297,164			69,300
Total current assets				5,738,025			3,373,354

Non-current assets
	Property and equipment	7		23,150			28,015
	Patents and intellectual property	8		62,362			88,167
			$	5,823,537		$	3,489,536

Liabilities and Shareholders' Deficiency
Current liabilities
	Trade payables and accrued liabilities	9	$	793,046		$	1,689,009
	Advances from distributor	6		495,494			1,778,112
	Current portion of finance lease obligation	10		3,690			2,982
Total current liabilities				1,292,230			3,470,103

Non-current liabilities
	Long-term portion of finance lease obligation	10		3,190			6,879
	Warrants	12		3,672,958			140,467
Total liabilities				4,968,378			3,617,449

Shareholders' Deficiency
	Share capital	13		27,242,071			24,658,241
	Stock-based payment reserve	14		970,004			62,495
	Warrants reserve			4,724,698			277,748
	Accumulated other comprehensive income			474,458			474,458
	Deficit			(32,556,072	)		(25,600,855	)
				855,159			(127,913	)
			$	5,823,537		$	3,489,536


LED MEDICAL DIAGNOSTICS INC.
Consolidated Statements of Financial Position
(Expressed in U.S. Dollars)

		Three months ended December 31, 2013			Three months ended December 31, 2012			Year ended December 31, 2013			Year ended December 31, 2012
Revenues		$	215,714		$	1,389,994		$	2,519,574		$	6,312,754
Cost of goods sold			424,018			747,510			1,348,223			2,745,477
			(208,304	)		642,484			1,171,351			3,567,277

Expenses
	Sales and marketing		434,577			349,248			1,252,688			2,564,798
	Research and development		120,623			94,980			442,880			523,492
	Administration		474,750			281,761			1,596,014			1,207,122
	Stock-based compensation		309,818			-			907,509			-
	Deferred share unit compensation		(149,967	)		-			230,613			-
	Other operating expenses		319,686			14,558			382,532			59,776
			1,509,487			740,547			4,812,236			4,355,188
Operating loss			(1,717,791	)		(98,063	)		(3,640,885	)		(787,911	)

Other expenses
	Mark to market adjustments on Canadian		545,259			(77,729	)		(3,277,328	)		(3,843	)
	dollar denominated warrants
	Foreign exchange (loss) gain		(280,322	)		1,161			(24,958	)		(64,511	)
	Other income		-			91			-			2,172
			264,937			(76,477	)		(3,302,286	)		(66,182	)
Net loss and comprehensive loss before income taxes			(1,452,854	)		(174,540	)		(6,943,171	)		(854,093	)

Income taxes			7,947						12,046			12,840

Net loss and comprehensive loss for the year		$	(1,460,801	)	$	(174,540	)	$	(6,955,217	)	$	(866,933	)


LED MEDICAL DIAGNOSTICS INC.
Consolidated Statements of Cash Flow
(Expressed in U.S. Dollars)

		Three months ended December 31, 2013			Three months ended December 31, 2012			Year ended December 31, 2013			Year ended December 31, 2012
Net loss for the year			($1,460,801	)	$	(174,539	)	$	(6,955,217	)	$	(866,933	)
Adjustments to net loss for items not involving cash:
	Depreciation of equipment		3,209			8,107			12,596			33,971
	Amortization of intellectual property		6,451			6,451			25,805			25,805
	Warrants issuance costs		310,026			-			344,131			-
	Loss on disposal of assets		-			-			-			702
	Accrued interest on shareholder loans		-			31			-			2,614
	Mark to market adjustments on Canadian dollar denominated warrants		96,402			77,729			3,022,165			3,843

	Deferred share unit compensation		230,613			-			230,613			-
	Stock-based compensation		309,818			-			907,509			-
			(504,282	)		(82,221	)		(1,902,072	)		(799,998	)
Changes in working capital assets and liabilities:
	Receivables		191,749			(620,813	)		1,010,841			(1,215,855	)
	Inventory		161,464			153,538			(115,840	)		474,150
	Inventory held by distributor		(44,632	)		-			352,568			(51,047	)
	Prepayments		(137,443	)		42,956			(227,864	)		(703	)
	Trades payable and accrued liabilities		(582,986	)		4,269			(895,963	)		290,024
	Advances from distributor		88,077			-			(1,282,618	)		320,750
Changes in working capital assets and liabilities			(323,771	)		(420,050	)		(1,158,876	)		(182,681	)
Cash flows used in operating activities			(828,053	)		(502,271	)		(3,060,948	)		(982,679	)
Cash flows from investing activities
	Purchase of equipment		(4,664	)		(4,098	)		(7,731	)		(16,758	)
	Restricted cash		4,853			59			5,026			19,556
Cash flows (used in) provided by investing activities			189			(4,039	)		(2,705	)		2,798
Cash flows from financing activities
	Issuance of common shares, net of issuance costs		4,209,809			1,081,513			6,451,600			1,081,513
	Issuance of share purchase warrants in private placement		4,436			-			4,436			-
	Repayment of finance lease obligation		(805	)		(651	)		(2,981	)		(2,410	)
	Repayment of shareholder loans		-			(31	)		-			(105,410	)
Cash flows (used in) provided by financing activities			4,213,440			1,080,831			6,453,055			973,693

Increase (decrease) in cash			3,385,576			574,521			3,389,402			(6,188	)
Cash, beginning of year			973,410			395,063			969,584			975,772
Cash, end of year		$	4,358,986		$	969,584		$	4,358,986		$	969,584